modeyso
(dordaviprone)Jazz Pharmaceuticals, Inc.
Usage: MODEYSO is indicated for treating adult and pediatric patients aged 1 year and older with progressive diffuse midline glioma harboring an H3 K27M mutation, following prior therapy. Approval is under accelerated conditions based on response rates, with continued approval potentially requiring further clinical confirmation.